Cargando…
Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy
BACKGROUND: Thymidine analogue resistance mutations (TAMs) selected under treatment with nucleoside analogues generate two distinct genotypic profiles in the HIV-1 reverse transcriptase (RT): (i) TAM1: M41L, L210W and T215Y, and (ii) TAM2: D67N, K70R and K219E/Q, and sometimes T215F. Secondary mutat...
Autores principales: | Betancor, Gilberto, Garriga, César, Puertas, Maria C, Nevot, María, Anta, Lourdes, Blanco, José L, Pérez-Elías, M Jesús, de Mendoza, Carmen, Martínez, Miguel A, Martinez-Picado, Javier, Menéndez-Arias, Luis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468358/ https://www.ncbi.nlm.nih.gov/pubmed/22889300 http://dx.doi.org/10.1186/1742-4690-9-68 |
Ejemplares similares
-
Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007) -
Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018) -
Eosinophilic Colitis Associated with Emtricitabine/Tenofovir
por: Lozier, Matthew R, et al.
Publicado: (2018) -
Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021) -
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
por: Micán, Rafael, et al.
Publicado: (2022)